bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/619312

Genome-wide CRISPR Screens Reveal Genetic Mediators of Cereblon Modulator Toxicity in Primary Effusion Lymphoma

Patil, A.·Manzano, M.·Gottwein, E.
View original source ↗Export metadata ↓

Abstract

Genome-wide CRISPR/Cas9 screens represent a powerful approach to study mechanisms of drug action and resistance. Cereblon modulating agents (CMs) have recently emerged as candidates for therapeutic intervention in primary effusion lymphoma (PEL), a highly aggressive cancer caused by Kaposis sarcoma-associated herpesvirus. CMs bind to cereblon (CRBN), the substrate receptor of the cullin-RING type E3 ubiquitin ligase CRL4CRBN, and thereby trigger the acquisition and proteasomal degradation of neosubstrates. Downstream mechanisms of CM toxicity are incompletely understood, however. To identify novel CM effectors and mechanisms of CM resistance, we performed positive selection CRISPR screens using three CMs with increasing toxicity in PEL: lenalidomide (LEN), pomalidomide (POM), and CC-122. Results identified several novel modulators of the activity of CRL4CRBN. The number of genes whose inactivation confers resistance decreases with increasing CM efficacy. Only inactivation of CRBN conferred complete resistance to CC-122. Inactivation of the E2 ubiquitin conjugating enzyme UBE2G1 also conferred robust resistance against LEN and POM. Inactivation of additional genes, including the Nedd8-specific protease SENP8, conferred resistance to only LEN. SENP8 inactivation indirectly increased levels of unneddylated CUL4A/B, which limits CRL4CRBN activity in a dominant negative manner. Accordingly, sensitivity of SENP8-inactivated cells to LEN is restored by overexpression of CRBN. In sum, our screens identify several novel players in CRL4CRBN function and define pathways to CM resistance in PEL. These results provide rationale for increasing CM efficacy upon patient relapse from a less efficient CM. Identified genes could finally be developed as biomarkers to predict CM efficacy in PEL and other cancers.\n\nKey PointsO_LIGenome-wide CRISPR/Cas9 screens identify novel mediators of resistance to lenalidomide, pomalidomide and CC-122 in PEL cells.\nC_LIO_LIUBE2G1 and SENP8 are modulators of CRL4CRBN and their inactivation drives resistance to CMs in PEL-derived cell lines.\nC_LI

Source connections

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Patil, A., Manzano, M., Gottwein, E.. 2019-04-25. Genome-wide CRISPR Screens Reveal Genetic Mediators of Cereblon Modulator Toxicity in Primary Effusion Lymphoma. https://doi.org/10.1101/619312

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

BCL10 Gain-of-Function Impairs Germinal Center Participation by Naive B Cells and Cooperates with BCL6 to Drive Extrafollicular Diffuse Large B-Cell Lymphoma

BCL10 gain-of-function (GoF) mutations occur in diffuse large B-cell lymphoma (DLBCL) cases of the BN2/C1 molecular subgroup. These alterations activate CARD11-BCL10-MALT1 (CBM) signaling and drive resistance to multiple drug classes, but their role in disease pathogenesis is incompletely understood. In particular, interactions between BCL10 GoF and additional DLBCL oncogenes are undefined. Here, we show BCL10 GoF in naive B cells blocks their participation in germinal center (GC) reactions and permits transformation to DLBCL with a non-GC B-cell phenotype. Most clinical cases with BCL10 GoF also carry translocation of the BCL6 proto-oncogene, and we show that co-activation of these two lesions together promotes pronounced oncogenic synergy. Detailed single-cell analyses of underlying premalignant B-cell populations revealed expansion of extrafollicular memory B cells whose gene-expression program remains prominent in resulting lymphomas in both the mouse and corresponding human tumors. We therefore define a novel role for BCL10 activating mutations in enabling BCL6 lymphomagenesis.

cancer biology↗
bioRxiv2026

Targeting NF-κB prevents Schwann cell reprogramming and plexiform neurofibroma initiation in mouse model of Nf1

Plexiform neurofibromas arise in approximately half of all individuals with Neurofibromatosis Type I (NF1). Genetic lesions apart from NF1 pathogenic variants are not present in NF1 mutant Schwann cells, suggesting that tumorigenesis may instead require cellular rewiring. To identify putatively re-wired tumor cells, we used multiplex imaging and flow cytometry to delineate markers that distinguish tumor Schwann cell from non-tumor Schwann cells. We identified tumor Schwann cells as CD44+;CD49f+ cells that show increased transcription of epithelial to mesenchymal plasticity (EMP)- associated genes. CD44+;CD49f+ expression was induced by treating Nf1-/- Schwann cells with stressors or by direct NF-{kappa}B pathway activation via IKK2; treated Schwann cells increased secretion of NF-{kappa}B targets and immune cell chemoattractants CCL2 and CCL3. In established tumors, MEK inhibition plus NF-{kappa}B blockade diminished tumor cell proliferation, tumor Schwann cells, immune cell populations, tumor cytokines and tumor number. Notably, transient single agent NF-{kappa}B pathway blockade was sufficient to significantly delay tumor formation in mice. Thus, Nf1 loss in Schwann cells is followed by NF-{kappa}B activation and cellular reprogramming that drives tumor initiation and targeting NF-{kappa}B activation can reduce NF1-deficient tumor formation.

cancer biology↗
bioRxiv2026

Response to azacitidine and the TIM-3 inhibitor, sabatolimab, in MDS and CMML is associated with distinct immune and antigen-presentation states

Targeting the immune checkpoint TIM-3 is of interest in myeloid neoplasms, yet the hematopoietic and immune changes associated with anti-TIM-3 therapy remain poorly characterized. We used single-cell RNA sequencing to profile bone marrow (BM) and peripheral blood from patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) treated with the hypomethylating agent azacitidine combined with sabatolimab, a monoclonal antibody targeting TIM-3, and integrated Human Cell Atlas reference datasets for comparison. CITE-seq profiling showed that TIM-3 was predominantly expressed on dendritic cells and NK cells, with variable expression across other populations, including CD34 cells and CD8 T cells. At baseline, we identified a population of CD34 myeloid-biased progenitors specific to MDS/CMML samples ("HSPC-like") characterized by inflammatory gene expression programs and features of impaired differentiation. In MDS, elevated baseline HLA class II expression across hematopoietic stem and progenitor cells (HSPCs), HSPC-like cells, and multiple myeloid populations was associated with response. Consistent with this finding, trajectory analysis suggested that nonresponders bypassed HLA class II-high states during myeloid differentiation. In MDS, the presence of distinct CD8 T-cell populations and increased interferon-response programs in CD8 T and NK cells at baseline was also associated with response. In both MDS and CMML, treatment among responders was associated with contraction of BM CD8 and CD4 T-cell populations characterized by type I interferon-responsive and inflammatory programs, including IFIT1, IFIT2, and TNF, along with expansion of a distinct GZMH/IFITM1-expressing cytotoxic CD8 T-cell population. Together, these findings identify baseline antigen-presentation and immune-response programs associated with therapeutic response and reveal coordinated remodeling of myeloid and lymphoid compartments during azacitidine/sabatolimab treatment in MDS and CMML.

cancer biology↗